Citius Oncology (CTOR) Consolidated Net Income (2023 - 2026)

Citius Oncology's Consolidated Net Income history runs 4 years deep, the most recent figure standing at -$26.6 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 243.99% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$42.5 million (down 121.78% YoY), while the FY2025 annual figure was -$24.8 million, down 17.08% from the prior year.
• Consolidated Net Income was -$26.6 million for Q1 2026 at Citius Oncology, down from -$5.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$147922.0 in Q1 2023 to a low of -$26.6 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$6.0 million across 4 years, with a median of -$4.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income sank 3168.98% in 2024, then increased 16.9% in 2025.
• A 4-year view of Consolidated Net Income shows it stood at -$4.7 million in 2023, then sank by 40.86% to -$6.7 million in 2024, then climbed by 16.9% to -$5.5 million in 2025, then plunged by 380.83% to -$26.6 million in 2026.
• The last three Consolidated Net Income figures came in at -$26.6 million (Q1 2026), -$5.5 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.